NYSE
$1.25▲ 0.40%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $55.7MShares out 44.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
24- 1d agoAfter-hours26.10.24 05:20DOther#●●●#●●●
OS Therapies Inc
OS Therapies Inc filed a Form D with the SEC on October 23, 2026, regarding an exempt offering of securities. The filing pertains to the company's capital raising activities, although specific details regarding the offering size or pricing terms were not disclosed.…more
$1.25+0.40%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoPre-market26.10.19 21:478-KKey event
OS Therapies Inc
OS Therapies completed an initial closing of a warrant exercise inducement and exchange offer, raising approximately $7.2 million in gross proceeds through the exercise of warrants for 5,517,253 shares. In exchange, the company issued new warrants to purchase up to 5,517,253 shares at an exercise price of $1.40, with proceeds intended to fund clinical development and regulatory activities.…more
$1.25+0.40%vs prev closeView filingShare - 10.5After-hours26.10.06 05:493Ownership
OS Therapies Inc
Kerry Clem, a shareholder of OS Therapies Inc, has executed a Power of Attorney authorizing Paul A. Romness, Francis Knuettel II, and Christopher P. Acevedo to act as attorneys-in-fact. This authorization allows them to execute and file required securities disclosures, including Schedules 13D, 13G, and Forms 3, 4, and 5, on behalf of the shareholder.…more
$1.25+0.40%vs prev closeView filingShare
23 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.7Pre-market26.10.07 21:40#●●●#●●●
OS Therapies Receives USDA Guidance for Canine Osteosarcoma Treatment
OS Therapies' subsidiary, OSAH, received feedback from the USDA regarding the commercial development pathway for its canine osteosarcoma treatment, OST-HER2. This guidance covers clinical efficacy, safety, and manufacturing requirements, serving as a prerequisite for a conditional licensure request.…more
$1.25+0.40%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.6Regular26.10.07 02:19
●●●●●●●● ●●●●● ●●●●●●
OS Therapies announced that its OST-HER2 bone cancer treatment demonstrated a statistically significant three-year survival benefit in a Phase 2b trial. The company plans to finalize regulatory submissions for market access in the U.S., U.K., Europe, and Australia by late 2026.…more
$1.25+0.40%vs prev closeShareBenzinga - 10.6Pre-market26.10.06 21:40
●●●●●●●● ●●●●● ●●●●●●
OS Therapies announced that its OST-HER2 treatment achieved a 72.7% three-year overall survival rate in a Phase 2b trial for pulmonary metastatic osteosarcoma, significantly outperforming the historical control. The company is now preparing regulatory submissions for early market access in the U.S., U.K., Europe, and Australia.…more
$1.25+0.40%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report